What gastritis actually means
The word breaks down simply: gastro (stomach) + itis (inflammation). Gastritis means the gastric mucosa — the lining of the stomach — is inflamed. But inflammation here doesn't mean temporary soreness. It means the immune system has been activated inside the stomach wall and that activation is not switching off.
The stomach lining is layered. On the surface: a thick mucus layer that shields tissue from stomach acid. Beneath it: epithelial cells, goblet cells that produce the mucus, and deeper glandular structures where acid and digestive enzymes are made. Chronic gastritis means these layers are being continuously damaged and cannot repair themselves at the same rate they're being broken down.
Acute vs chronic — why the distinction matters
Acute gastritis arrives suddenly and for a reason. Too much ibuprofen. A rough night of alcohol. A stomach virus. The lining inflames and, once the trigger is removed, it heals. Acute gastritis is self-limiting.
Chronic gastritis is a different condition entirely. It develops slowly — often over months or years — and does not resolve on its own. The trigger, in most Indian cases H. pylori bacteria living inside the stomach lining, hasn't been removed. The immune system stays activated. Damage accumulates faster than the repair can keep pace.
Acute: trigger arrives → inflammation spikes → trigger leaves → healing. Chronic: trigger persists → continuous inflammation → structural changes accumulate → symptoms never fully clear. Antacids are built for the first scenario. They do nothing about the trigger driving the second.
What is happening inside the stomach lining
Most patients are never told this part. In active chronic gastritis, four processes run simultaneously:
Goblet cells responsible for producing protective mucus are damaged. The barrier between stomach acid and the underlying tissue gets thinner — increasing direct acid contact with an already-inflamed surface.
Neutrophils and lymphocytes flood the lining to fight the persistent bacterial threat. This immune activity — visible on endoscopy as redness and mucosal swelling — is what earns the "gastritis" label in the report.
Cytokines — particularly IL-8 and TNF-α — are continuously released. These disrupt normal cell turnover: damaged epithelial cells are replaced more slowly than they're being lost, widening net damage over time.[2]
Over years of unaddressed inflammation, the acid-secreting glands thin and lose function — a stage called atrophic gastritis. This is harder to reverse and carries greater long-term clinical risk than superficial gastritis caught earlier.
What causes chronic gastritis in India?
The dominant cause in India is H. pylori infection.[1] The bacteria colonise the antral mucosa, trigger NF-kB-mediated immune activation, and release cytotoxins that directly damage goblet cells — creating exactly the four-stage environment described above. In TumGard's endoscopy cohort, the 24% gastritis rate and 62% H. pylori rate substantially overlap. In most cases of chronic gastritis in India, you are looking at the same patient and the same root problem.
Of 1,111 TumGard buyers who underwent endoscopy, 24% had confirmed gastritis, 62% had H. pylori, and only 5.8% had an entirely normal result. 54% had been on antacids or PPIs throughout — managing acid while the underlying inflammation continued unchecked.
Other causes include long-term NSAID use, excessive alcohol, autoimmune gastritis, and bile reflux. In younger Indian adults without autoimmune conditions or heavy NSAID history, H. pylori accounts for the large majority of chronic cases.
Why a PPI doesn't fix it
A proton pump inhibitor blocks the hydrogen-potassium ATPase enzyme in gastric parietal cells — the acid pump. Output drops, the burning sensation eases, the mucosal environment becomes less hostile while inflamed. As a short-term measure, this is reasonable.
What a PPI does not do: eliminate H. pylori, reduce the NF-kB inflammatory cascade, repair damaged goblet cells, stimulate mucus production, or reverse the structural thinning of the lining. It addresses the pain signal — acid exposure — without touching the biology producing the damage.
Long-term PPI use causes parietal cell hyperplasia — the acid-producing cells multiply in response to being suppressed. When the PPI is stopped, acid surges above baseline. This isn't the gastritis getting worse; it's the body overcorrecting. But it makes stopping feel impossible, and patients remain on PPIs for years longer than intended while the underlying inflammation continues untouched.
What recovery from chronic gastritis actually requires
For H. pylori-driven chronic gastritis, three things need to happen in parallel:
- Targeting the bacterial driver. H. pylori needs to be addressed directly — through antibiotic eradication therapy or through compounds that inhibit its ability to survive and adhere to the stomach wall.
- Dampening the inflammatory cascade. The NF-kB signalling H. pylori triggers needs to be reduced. Quercetin has documented NF-kB inhibitory activity at relevant concentrations, reducing the cytokine load on damaged tissue.[3]
- Supporting mucosal repair. The goblet cells and EGFR/ERK repair pathway that rebuild the mucus layer need the right conditions to function. Licorice-derived glabridin activates this pathway directly.[2]
In TumGard's data, 37% of buyers had been symptomatic for more than three years. Most had been on acid suppression throughout. The lining had no opportunity to repair because none of the three repair requirements were ever met.
References
- Crowe SE. Helicobacter pylori infection. New England Journal of Medicine. 2019;380(12):1158–1165. PMID 30699316. Authoritative clinical review establishing H. pylori as the primary cause of chronic active gastritis — foundational reference for this article's causal framing.
- Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defence and cytoprotection: bench to bedside. Gastroenterology. 2008;135(1):41–60. PMID 18424695. Comprehensive review of gastric mucosal defence — goblet cells, mucus layer structure, EGFR/ERK repair pathway, prostaglandins. The biological basis for the four damage stages described in this article.
- Ye YN, Liu ES, Shin VY, Wu WK, Cho CH. Modulating role of nuclear factor-κB in the gastroprotective action of flavonoids. Journal of Ethnopharmacology. 2023. PMID 36842733. Documents quercetin NF-kB inhibitory activity and licorice flavonoid-mediated EGFR/ERK mucosal repair — mechanistic basis for the recovery requirements described in this article.
- Merlin Annie Raj, RD. TumGard India Gut Health Report 2026. Hugg Beverages Pvt. Ltd. 2026. tumgard.com/india-gut-health-report-2026. Source of the 24% gastritis confirmation rate, 62% H. pylori rate, 86% significant finding rate, and 37% three-year symptom duration figure. Endoscopy sub-cohort n=1,111.
The 24% gastritis confirmation rate reflects a symptomatic population — not the general public. Indian clinical studies on endoscopy findings in symptomatic adults consistently show gastritis in 30–50% of cases (Crowe, NEJM 2019), making TumGard's figure consistent with the lower end of that range. The 86% clinically significant finding rate aligns with Indian clinical literature showing that endoscopy in symptomatic gut patients rarely returns entirely normal.